The downregulated membrane expression of CD18 in CD34+ cells defines a primitive population of human hematopoietic stem cells

Cristina Mesa-Núñez 1,2,3†, Diego Leon-Rico 1,2,3†, Montserrat Aldea 1,2,3, Carlos Damián 1,2,3, Raquel Sanchez-Baltasar 1,2,3, Rebeca Sanchez 1,2,3, Omaira Alberquilla 1,2,3, José Carlos Segovia 1,2,3, Juan Antonio Bueren 1,2,3 and Elena Almarza 1,2,3*

Abstract

Background: CD18 is the common beta subunit of β2 integrins, which are expressed on hematopoietic cells. β2 integrins are essential for cell adhesion and leukocyte trafficking.

Methods: Here we have analyzed the expression of CD18 in different subsets of human hematopoietic stem and progenitor cells (HSPCs) from cord blood (CB), bone marrow (BM), and mobilized peripheral blood (mPB) samples. CD34+ cells were classified into CD18high and CD18low/neg, and each of these populations was analyzed for the expression of HSPC markers, as well as for their clonogenity, quiescence state, and repopulating ability in immunodeficient mice.

Results: A downregulated membrane expression of CD18 was associated with a primitive hematopoietic stem cells (HSC) phenotype, as well as with a higher content of quiescent cells and multipotent colony-forming cells (CFCs). Although no differences in the short-term repopulating potential of CD18low/neg CD34+ and CD18high CD34+ cells were observed, CD18low/neg CD34+ cells were characterized by an enhanced long-term repopulating ability in NSG mice.

Conclusions: Overall, our results indicate that the downregulated membrane expression of CD18 characterizes a primitive population of human hematopoietic repopulating cells.

Keywords: Hematopoietic stem cells, CD18, Integrins, Long-term repopulating cells

* Correspondence: elenaalmarza@gmail.com
† Cristina Mesa-Núñez and Diego Leon-Rico contributed equally to this work.
1 Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Av. Complutense 40, 28040 Madrid, Spain
2 Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Melchor Fernández Almagro 3, 28029 Madrid, Spain
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Significance statement
This study demonstrates that CD18 is a marker whose membrane expression is inversely correlated with the primitiveness of human CD34+ cells. The selection of CD34+ cells with a reduced expression of CD18 defines a primitive population with an extended repopulating ability as compared with CD34+ cells expressing higher levels of CD18.

Background
Integrins are heterodimeric adhesion molecules that mediate intercellular interactions and cell interactions with the extracellular matrix. β2 integrins are composed by a common β2 subunit (CD18) and variable α subunits (CD11). The expression of β2 integrins is restricted to the hematopoietic system. This integrin subfamily includes four members, whose identity depends on the particular α subunit of the heterodimer. Heterodimers comprised of CD18:CD11A (LFA-1), CD18:CD11B (Mac-1), CD18:CD11C (p150.95), and CD18:CD11D (α5β2) are associated with distinct patterns of expression and function in the hematopoietic system [1–3]. All leukocytes express the lymphocyte function-associated antigen 1 (LFA-1) on their surface. LFA-1 is mainly involved in the leukocyte adhesion cascade and also in the immune synapse formation between T cells and antigen-presenting cells (APCs). Macrophage 1 antigen (Mac-1) is mostly expressed in the myeloid lineage, where it mediates a range of functions such as phagocytosis, degradation, and remodeling of the extracellular matrix. Integrin p150.95 is expressed in myeloid cells, dendritic cells, NK cells, and populations of activated T and B cells. It mediates phagocytosis of inactive complement component 3b (iC3b)-opsonized particles and it is involved in the adhesion of monocytes to endothelial cells. Integrin α5β2 is expressed at a basal level on the surface of most leukocytes and is upregulated on phagocytic leukocytes present in regions of local inflammation, although its specific role in leukocyte function remains unknown [3].

Bone marrow HSPCs display a variable expression of LFA-1, although its expression is downregulated by interactions with stromal cells. In the presence of stimulating chemokines, the immune system responds by inducing the proliferation of the HSCs in the BM. In this process, cells which lose stromal interaction will rapidly upregulate LFA-1 expression enabling migration to the periphery [4]. Overall, previous reports consistently showed that LFA-1− cells are more pluripotent than LFA-1+ cells. Supporting data include a demonstration that LFA-1+ cells generate more CFUs in long-term BM cultures than the LFA-1− population. It has been postulated that LFA-1 could play a role in the interaction between stromal cells and HSCs, thus allowing HSCs to migrate through the different environments of the stroma [5], but may not be needed for the interaction between the stroma and the most primitive HSCs, implying that LFA-1 expression is not an absolute requirement for the earliest stages of hematopoiesis [6]. When studied in mouse models, the transplantation of CD11A− HSCs (defined as Lin−c-Kit+Sca1−CD150−CD34+) resulted in higher engraftment as compared to similar numbers of CD11A+ HSCs, not only in primary but also in secondary recipients. The absence of this marker was also associated with a higher frequency of HSCs in the G0 phase of the cell cycle [7], suggesting that the reduced expression of CD11A was associated with primitive HSCs. Similarly, in nonhuman primates, it has been reported that HSCs capable of repopulating both lymphoid and myeloid lineages are also included in the CD34+/CD11B− fraction [8].

Because the common link between the expression of CD11B and CD11A in the leukocyte membrane is the β2 subunit (CD18), in the current study, we aimed at providing conclusive evidence regarding the relevance of CD18 expression in human HSPCs. Thus, we investigated the HSPC phenotype and repopulating properties of cord blood, BM, and also mPB CD34+ cells either positive or negative for the expression of CD18.

Methods
Purification and culture of cord blood CD34+ cells
Cord blood samples from healthy donors were obtained from the Madrid Community Transfusion Centre under their Institutional Review Board (IRB) approval and their written informed consent and in compliance with the Helsinki Declaration. Mononuclear cells were isolated by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare, Fairfield, USA). These cells were CD34+ magnetic-labeled with CD34 MicroBead Kit and separated from the total mononuclear population using LS QuadroMACS™ and MS OctoMACS™ columns (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany). Purified CD34+ cells were then evaluated for their purity by Flow Cytometry Activated Cell Sorting (FACS), which is regularly around 80–95%.

Freshly isolated CD34+ cells were cultured in StemSpan medium (StemCell Technologies, Vancouver, Canada) supplemented with 300 ng/ml hSCF, 100 ng/ml hTPO, 100 ng/ml hFlt3L (Eurobiosciences, Friesoythe, Germany), 1% penicillin/streptomycin (P/S), and 1% GlutaMAX (Gibco/Life Technologies/Thermo Fisher Scientific, Waltham, USA) at 37 °C in 5%CO2.

With the aim of characterizing the phenotype and functional properties of CD34+ cells based on different levels of CD18 expression, the clone 6.7 of the monoclonal antibody against CD18 was selected to assure recognition of
Flow cytometry analyses and cell sorting

Flow cytometry analyses were performed in the LSRFortessa cell analyzer (BD/Becton, Dickinson and Company, New Jersey, USA). Off-line analyses were made with the FlowJo Software v7.6.5. (Tree star, Ashland, USA).

More than $1 \times 10^4$ viable cells were acquired in the LSRFortessa cell analyzer using 1 μg/ml DAPI as a viability marker suspended in flow cytometry buffer consisting of phosphate-buffered saline with 0.5% bovine serum albumin and 0.05% sodium azide. Peripheral Blood (PB) and BM samples were previously lysed in ammonium chloride lysis solution (0.155 mM NH₄Cl, 0.01 mM KHCO₃, 10−3 mM EDTA).

The human (h) CD18 antibody used was the 6.7 clone (#551060, BD Bioscience). For the study of the very primitive phenotype of the HSCs, hCD34 (#25-0349-41, eBioscience, San Diego, CA, USA), hCD38 (#302522, Biolegend, San Diego, CA, USA), hCD90 (#555596, BD), and hCD45RA (#470458, eBioscience) markers were used and hCD18 (#551060, BD Biosciences) was added as an additional label. Gating strategy used for the analyses of progenitors is included in Fig. S1. Analyses of integrins CD18 and CD49f were performed with clones 6.7 (#551060, BD Biosciences) and GoH3 (#563271, BD Biosciences), respectively.

For cell sorting, freshly isolated CD34+ cells obtained from cord blood, as has previously been described, were stained with hCD18 (#551060, BD Bioscience) and hCD34 (#345802, BD Bioscience) monoclonal antibodies and were FACS-sorted using BD INFLUX (BD Biosciences) to separate CD34+CD18high and CD34+CD18low/neg populations. Cell sorting strategy is included in Fig. S4.

Clonogenic studies of hematopoietic progenitor cells

CFCs assays were performed in a methylcellulose-based media (#130-091-280 MACS, Miltenyi Biotec). Triplicates of 250 cells from each condition (CD34+CD18high and CD34+CD18low/neg sorted cells or CD34+ total population) were cultured for 24 h, were plated in 35 mm dishes (#430165, Corning, New York, USA), and were grown at 37 °C in 5%CO₂. Fourteen days after culture, colonies were observed by inverted microscope (Nikon Phase Contrast ELWD 0.3133909, Japan) to identify the different hematopoietic precursors: colony-forming unit granulocyte-macrophage (CFU-GM), burst-forming unit erythroid (BFU-E), and colony-forming unit granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM).

Cell cycle analyses

For the cell cycle analysis, $1.5 \times 10^6$ purified CD34+ cells from cord blood were suspended in Hoeschst Binding Buffer (Hank’s Balanced Salt Solution, containing 20 mM HEPES, 5.5 mM glucose and 10% HyClone) and stained for DNA and RNA with Hoeschst 33342 (Sigma-Aldrich, St. Louis, Missouri, USA) for 45 min at 37 °C in darkness. Then, pyronin Y (#P9172-IG, Sigma-Aldrich) was added and cells were incubated in the same conditions. Finally, cells were surfaced stained with hCD34 (#555824, BD), hCD38 (#303522, BioLegend), and hCD18 (#555923, BD Pharmingen) monoclonal antibodies and were analyzed by flow cytometry.

Animals

NOD-scid IL2Rγnull (NSG) mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and maintained in micro-isolators. The experimental procedures involving mice were carried out at the CIEMAT animal facility (registration number 28079-21 A). Mice were maintained under high standard conditions (high-efficiency particulate-filtered air, regulated temperature of 22 °C, light/dark cycle of 12 h, and food and ultraviolet-irradiated water ad libitum) and routinely screened for pathogens.

All experimental procedures were carried out according to Spanish and European regulations (Spanish RD 53/2013 and Law 6/2013 that translate and comply with the European Directive 2010/63/UE about the use and protection of vertebrate mammals used for experimentation and other scientific purposes).

Xenotransplants in NSG mice

NSG mice were irradiated with 1.5 Gy 24 h prior transplantation. Approximately $10^5$ CD34+ cells were transplanted into NSG mice by retro-orbital injection. Once a month, bone marrow aspirations were performed to analyze in BM cells the engraftment and lineage distribution by FACS, using hCD45 (#304014, BioLegend), hCD19 (#25-0198, eBioscience), hCD33 (#A07775, Beckman Coulter), hCD34 (#555824, Becton Dickinson), and CD18 (#555923 or #551060, BD Pharmingen) monoclonal antibodies. Transplanted mice were culled at 3 months post-transplantation (mpt) and total bone marrow cells (BMCs) were also analyzed by FACS with the same antibodies. Human CD45+ magnetic-labeled cells were selected using CD45 MicroBead Kit (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) and secondary transplants in NSG mice were performed with comparable number of cells in all groups ($3–5 \times 10^6$ cells per mouse). After 3 months follow-up, secondary recipients were sacrificed by cervical dislocation and BM and PB samples were analyzed by flow cytometry.

Limiting dilution assay

CD34+ from cord blood samples were sorted out to purify CD34+CD18high and CD34+CD18low/neg populations as described in Fig. S4. These cells were transplanted...
into 1.5 Gy irradiated NSG mice at different cell doses (15,000, 2000, and 200 cells/mouse) by retro-orbital injection. Ten months after transplantation, animals were sacrificed by cervical dislocation and BM cells were harvested and analyzed by flow cytometry for the presence of human hematopoietic cells, as well as for myeloid and B cells using hCD45\(^+\) (#A07782, Beckman Coulter, Brea, CA, USA), hCD33 (#A07775, Beckman Coulter), and hCD19 (#363012, BioLegend) monoclonal antibodies. Results were analyzed using the ELDA software, as described by Hu and Smyth [9].

**Statistical analyses**

The statistical analysis was performed using GraphPad Prism version 7.00 for Windows (GraphPad Software, San Diego, USA, www.graphpad.com). For comparison of qualitative and quantitative variables in which the sample size \( n \) < 30 or data did not follow a normal distribution, deduced from Kolmogorov-Smirnov test, Kruskal-Wallis test was performed to elucidate the significance of differences in the whole group. If samples showed significant differences, established when \( P < 0.05 \), a nonparametric two-tailed Mann-Whitney test was performed.

---

**Fig. 1** Flow cytometry analyses of CD18 expression in different cord blood HSPCs populations. **a** Analysis of the proportion of CD18\(^{\text{high}}\) and CD18\(^{\text{low/neg}}\) cells in different HSPCs present in nucleated cord blood cells. Percentages in the total nucleated cord blood cell population are shown. **b** Percentage of CD18\(^+\) cells in different HSPCs analyzed in purified CD34\(^+\) cord blood samples. **c** Percentage of HSPCs in purified CD34\(^+\) cells expressing high (CD18\(^{\text{high}}\)) or low levels (CD18\(^{\text{low/neg}}\)) of CD18. In panels **b** and **c**, CD34\(^+\) cells were purified by magnetic sorting prior to conducting flow cytometry studies. The significance of differences between groups is expressed as \( P < 0.0001 \) (****), \( P < 0.001 \) (***), \( P < 0.01 \) (**), or \( P < 0.05 \) (*)
was performed to obtain the \( P \) value or the adjusted \( P \) value when Dunn’s multiple comparison test was applied. The significances are expressed as \( P < 0.0001 \) (****), \( P < 0.001 \) (***) , \( P < 0.01 \) (**), or \( P < 0.05 \) (*).

**Results**

The low/negative expression of CD18 defines a primitive phenotype of cord blood CD34+ cells

In a first set of studies, mononuclear CB cells were classified based on their CD18 expression as CD18\textsuperscript{high} and CD18\textsuperscript{low/neg} (gating strategy Fig. S1A). In each of these two populations, the content of CD34\textsuperscript{+}, CD34\textsuperscript{−}CD38\textsuperscript{−}, CD34\textsuperscript{−}CD38\textsuperscript{−}CD45RA\textsuperscript{−}, and CD34\textsuperscript{−}CD38\textsuperscript{−}CD45RA\textsuperscript{−}CD90\textsuperscript{+} was analyzed. These analyses revealed that the proportion of CD34\textsuperscript{+} cells was significantly higher (5-fold) in the CD18\textsuperscript{low/neg} fraction as compared to CD18\textsuperscript{high} cells. Also, evident increases in primitive populations were observed in the CD18\textsuperscript{low/neg} fraction when other HSC markers were considered. Significantly, the proportion of very primitive CD34\textsuperscript{−}CD38\textsuperscript{−}CD45RA\textsuperscript{−}CD90\textsuperscript{+} HSCs was 23 times higher in the CD18\textsuperscript{low/neg} population as compared to the CD18\textsuperscript{high} population (7 \times 10\textsuperscript{−3}% vs 4 \times 10\textsuperscript{−4}%, respectively) (Fig. 1a), confirming that the reduced expression of CD18 was associated with an increased proportion in cells with a primitive HSC phenotype. Thereafter, the proportion of CD18\textsuperscript{+} cells was investigated in CD34\textsuperscript{−}-enriched HSCs according to CD34, CD38, CD45RA, and CD90 markers (gating strategy Fig. S1B). In contrast to data obtained in CD34\textsuperscript{−} cells, where 65% of these cells were CD18\textsuperscript{+}, only 25% of the CD34\textsuperscript{+} or CD34\textsuperscript{−}CD38\textsuperscript{−} cells were CD18\textsuperscript{+}. Moreover, this percentage was markedly decreased when CD34\textsuperscript{+} cells with a more primitive phenotype (CD34\textsuperscript{−}CD38\textsuperscript{−}CD45RA\textsuperscript{−} or CD34\textsuperscript{−}CD38\textsuperscript{−}CD45RA\textsuperscript{−}CD90\textsuperscript{+} cells) were analyzed (Fig. 1b). Similar studies were conducted with BM and mPB cells. As observed in CB samples, in both cases, the proportion of CD18\textsuperscript{+} cells was decreased in populations defined by a primitive HSC phenotype (Fig. S2). Consistent with the above observations, when CD34\textsuperscript{+} cells were sorted, analyses of CD18\textsuperscript{high} and CD18\textsuperscript{low/neg} populations confirmed a higher proportion of cells with a primitive HSC.

![Fig. 2](image_url)  
**Fig. 2** Assessment of the colony-forming cell content in different cord blood CD18 expressing populations. a Analysis of the content of total CFCs per 10^5 seeded cells and b distribution of the different types of CFCs in CD34\textsuperscript{+} cells sorted on the basis of CD18 expression. CFU-GM, BFU-E, and CFU-GEMM are shown. The significance of differences between total and CD18\textsuperscript{high} or CD18\textsuperscript{low/neg} sorted populations is shown as \( P < 0.01 \) (**), or \( P < 0.05 \) (*). The significance of differences between CD18\textsuperscript{high} and CD18\textsuperscript{low/neg} populations is shown as \( P < 0.001 \) (###) or \( P < 0.01 \) (##).
phenotype observed in all instances in CD18 low/neg cells as compared to CD18 high cells (Fig. 1c).

Recently published papers have shown the close relationship between different integrin’s expression and the primitiveness of HSCs. Particularly, the expression of integrin α6 (CD49f) in HSCs has been correlated with long-term multi-lineage repopulation ability in NSG mice. Thus, we have compared the expression levels of CD49f with CD18 in CD34+ and CD34+CD38− populations [10]. As observed in Fig. S3, no co-expression of CD18 was observed in CD49f+ cells in these HSPC populations.

In subsequent studies, the content of CFCs was assessed in purified CB CD34+ cells and in CD34+CD18 high and CD34+CD18 low/neg populations (see gating strategy in Fig. S4). Figure 2 shows the results in which seven CB samples were analyzed. While no significant differences were observed in the total number of colonies generated from these three different cell populations (Fig. 2a), significant changes were observed in the distribution of the different types of colonies. Whereas the proportion of BFU-E and CFU-GEMM colonies was significantly higher in CD34+CD18 low/neg cells, this fraction contained a significantly lower number of CFU-GM colonies as compared to the other two ones (Fig. 2b). Since a characteristic primitive HSC phenotype is their resting state, in the next set of experiments, we investigated the percentage of cells in the G0 phase in purified CD34+CD18 low/neg and CD34+CD18 high cells. As shown in Fig. 3a, a significant increase in the proportion of cells in G0 was observed in CD34+CD18 low/neg as compared to CD34+CD18 high cells (8.5% vs 1.2%, respectively). A higher proportion of cells in G0 was even observed when primitive CD34+CD38−CD18 low/neg cells were analyzed (19%), while only 1.8% of CD34+CD38−CD18 high cells were in G0.

Taken together, the results of these in vitro studies indicate that the low membrane expression of CD18 in purified HSPCs endows a population with a high content in erythroid and mixed CFCs and with a high content in quiescent cells.

The low/negative expression of CD18 defines HSPCs with extended repopulating ability

In an attempt to quantify the HSC content in CD34+CD18 high and CD34+CD18 low/neg cells, a limiting dilution assay was performed. A total of 44 mice were transplanted with different numbers of purified CD34+CD18 high or CD34+CD18 low/neg CB cells. The evaluation of the human hematopoietic repopulation was always assessed at 2.5 months post-transplantation (Fig. S5A). Animals were considered positive when at least 0.1% hCD45+, hCD33+, and hCD19+ cells were determined in recipient BM. Data from the Extreme Limiting Dilution Analysis (ELDA; Fig. S5B) revealed that no significant differences in the content of short-term hematopoietic repopulating cells were observed between the CD34+CD18 high and CD34+CD18 low/neg cell populations.

Due to this striking observation, we investigated potential differences in the stemness of CD34+CD18 high and CD34+CD18 low/neg cells by conducting additional re-population studies in NSG mice. In these studies, 100,000 CD34+CD18 low/neg or CD34+CD18 high cells were transplanted into NSG mice. Levels of engraftment were then analyzed at different times post-transplantation and also after re-transplantation into secondary recipients. Although a similar proportion of BM hCD45+ cells was observed in analyses conducted at 1 mpt, higher levels of hCD45+ cells were observed at 2 and 3 mpt in mice transplanted with CD34+CD18 low/neg cells compared to the CD34+CD18 high group (Fig. 4a). In both groups, similar distributions of hCD34+, hCD19+, and hCD33+ populations were observed in hCD45+ engrafted cells.
Neither differences in the proportion of CD18+ cells were found in hCD34+, hCD19+, and hCD33+ cells generated in mice transplanted with CD34+CD18low/neg or CD34+CD18high cells (Fig. 4c), revealing the re-expression of CD18 in hematopoietic cells generated from the primitive CD34+CD18low/neg repopulating cells. At 3 mpt, primary recipients from each of the two recipient groups were sacrificed and BM cells were pooled and hCD45+ cells purified by magnetic cell sorting. The same number of hCD45+ cells was then transplanted into secondary NSG recipients to evaluate the long-term repopulating ability of CD34+CD18high and CD34+CD18low/neg cells that had been transplanted into primary recipients. Remarkably, the proportion of CD45+ cells in the BM of secondary recipients was around 10-fold higher in secondary recipients corresponding to the CD34+CD18low/neg group (Fig. 4d), confirming the enhanced long-term repopulation ability of CD34+CD18low/neg cells as compared to CD34+CD18high cells.

**Discussion**

Due to the difficulties in the identification of a unique marker characteristic of primitive HSCs, several marker combinations have been proposed, which have markedly improved our knowledge about the functional properties of HSCs, and also enabled the classification and sorting of these cells for different biological and clinical applications. Although the CD34+ marker is the most frequently used in clinical practice, there is a strong consensus that Lin−CD34+CD38−CD45RA−CD90+ cells constitute a highly purified population of self-renewing HSCs [11, 12].

Among the other markers that have been used for the characterization of the HSCs, the membrane expression of certain β integrins has been observed in very primitive HSC subsets and has shown the functional role of these integrins in HSCs. This was the case of CD49b (integrin α2), whose expression in CD34+CD38− cells and also in the more primitive CD34+CD38−CD90+ population correlated with the long-term repopulating ability of these cells in NSG mice [13]. Likewise, expression of CD49f (integrin α6) has been observed in HSC subsets with long-term multi-lineage repopulation ability in NSG mice. Thus, the very primitive HSCs have been defined as a Lin−CD34+CD38−CD45RA−CD90−CD49f+ population, this last marker being absent in more differentiated multipotent progenitor cells [10]. Additionally, the
expression of CD49d (integrin α4) has also been associated with the primitiveness of the HSCs and involved in the homing of adult HSCs in BM [14]. Although previous studies have shown the role of certain integrins in the interaction of HSCs with other cells in the BM niche [6, 15–17], in the case of β2 integrins, previous studies have revealed the lack of expression of both CD11A and CD11B subunits in primitive HSCs [4–8]. Additionally, no studies have been performed to elucidate the implication of CD18 expression in the HSPC phenotype.

Our first set of studies showed that CD18low/neg cells contain a higher proportion of primitive HSCs defined by the following expression markers: CD34−CD38−CD45RA+CD90+. Functionally, CD18low/neg cells were enriched in CFU-GEMM, more primitive than the CFU-GM progenitors. Additionally, a higher content of cells in G0 was observed in primitive than the CD18high progenitors. A similar analysis was performed in the CD38−population gated inside the CD34+. The CD90+CD45RA+ population selected inside these CD38−cells was also asked for the percentage of CD18high and CD18low/neg populations.

Conclusion

Taken together, our results show that the low/negative expression of CD18 constitutes a reliable marker which defines a subpopulation of primitive CD34+ cells with extended long-term Losada for their collaboration in the administrative work. The authors would also like to thank in vivo repopulating ability.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s13287-020-01672-0.

Additional file 1: Figure S1. Schematic representation of the gating strategy. (A) Gating strategy for Fig. 1A and C. Nucleated cord blood cells were labeled using hCD18, hCD34, hCD38, hCD90 and hCD45RA. The gating strategy started with the selection of CD18high and CD18low/neg populations. Inside each of these groups of cells, CD34+ population was selected. Then, the CD38−population was chosen inside the CD18highCD34+ and CD18low/negCD34+ fractions. These two groups (CD18highCD34+ and CD18low/negCD34+) were asked for the percentage of both CD90+ and CD45RA+ populations. (B) Gating strategy for Figure 1B. The percentage of CD18+ and CD18−populations was determined in the CD34+ population. A similar analysis was performed in the CD38−population gated inside the CD34+. The CD90+CD45RA−population selected inside these CD38−cells was also asked for the percentage of CD18high and CD18low/neg populations.

Additional file 2: Figure S2. Flow cytometry analyses of CD18 expression in CD34+ CD34− and CD38−CD34+ CB cells from BM and mPB. Percentage of CD18+ cells in different HSPCs from BM (A) or mPB (B). The significance of differences between groups is expressed as P<0.05 (*).

Additional file 3: Figure S3. Flow cytometry analyses of integrins CD49F and CD18 in purified CD34+ cells from cord blood samples. Histograms represent data from three independent CB samples analyzed for the percentage of CD18 and CD49F expressing cells in two different subsets of progenitor populations: CD34+ and CD34−CD38−.

Additional file 4: Figure S4. Gating strategy for the cell sorting of CD34+ cells based on the expression of CD18. Histograms represent data from three independent CB samples sorted out based on CD34 and CD18 expression.

Additional file 5: Figure S5. Limiting dilution assay deduced from the transplantation of CD34+CD18high and CD34+CD18low/neg CB cells. Limiting dilution assay performed with CD34+CD18high and CD34+CD18low/neg CB cells transplanted into NSG mice. Purified CD34+CD18high and CD34+CD18low/neg CB cells from three different pools of CB samples were transplanted into immunodeficient NSG mice. Ten weeks after the infusion (2.5 mpt), BM cells were harvested and analyzed by flow cytometry for the presence of hCD45+ cells. (A) Table summarizing the number of engrafted mice (mice with ≥ 0.1% hCD45+ cells and ≥ 0.1% hCD33+ and ≥ 2 hCD19+ cells) per total number of transplanted mice in each cell dose, as well as the stem cell frequency in a 95% confidence interval. Analyses were performed using the ELDA software [9]. (B) Log-fraction plot of the limiting dilution model. Slope of solid lines shows the active cell fraction. Dotted lines represent the 95% confidence interval. Triangles symbolize groups with no negative response (CD34+CD18high and CD34+CD18low/neg at 15,000 cell dose).

Abbreviations

APC: Antigen-presenting cell; BFU-E: Burst-forming unit erythroid; BM: Bone marrow; CB: Cord blood; CFC: Colony-forming cell; CFU-GEMM: Colony-forming unit granulocyte, erythroid, macrophage, megakaryocyte; CFU-GM: Colony-forming unit granulocyte-macrocyte; ELDA: Extreme limiting dilution assay; FACS: Flow Cytometry Activated Cell Sorting; HSCs: Hematopoietic stem cells; HSPC: Hematopoietic stem and progenitor cell; IRB: Institutional Review Board; LFA-1: Lymphocyte function-associated antigen 1; Mac-1: Macrophage 1 antigen; mPB: Mobilized peripheral blood; PB: Peripheral blood; P/S: Penicillin/streptomycin

Acknowledgments

The authors would like to thank Miguel Angel Martin, Jesús Martínez, and Edilla de Almeida for the careful maintenance of the animals and Aurora de la Cal, Mª del Carmen Sanchez, and Sergio Losada for their collaboration in the administrative work. The authors would also like to thank the Madrid Community Transfusion Center for the cord blood human samples.

Authors’ contributions

CMN: Collection and/or assembly of data, data analysis and interpretation, manuscript writing. DLR: Collection and/or assembly of data, data analysis
and interpretation. MA: Collection and/or assembly of data. CD: Collection and/or assembly of data. RSB: Collection and/or assembly of data. RS: Collection and/or assembly of data, data analysis and interpretation. OA: Collection and/or assembly of data. JCS: Data analysis and interpretation. JAB: Conception and design, data analysis and interpretation, manuscript writing, final approval of the manuscript. EA: Conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of the manuscript. The author(s) read and approved the final manuscript.

Funding
This work was supported by the following grants: Dirección General de Investigación de la Comunidad de Madrid (CellCAM, Ref.25010/BMD-2420), Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III (RETICS-RD12/0019/0023), and Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad (SAF2017-86749-R). DLR and CMN were supported by FPU grants by the Spanish Ministry of Education and Training (AP-2009-4129 and FPU-15/03410, respectively).

Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Ethics approval and consent to participate
Human cord blood samples from healthy donors were obtained from the Madrid Community Transfusion Centre under their IRB approval and their written informed consent and in compliance with the Helsinki Declaration. The experimental procedures involving mice were carried out at the CIEMAT animal facility (registration number 28079-21 A). All experimental procedures were carried out according to Spanish and European regulations (Spanish RD 53/2013 and Law 6/2013 that translate and comply with the European Directive 2010/63/UE about the use and protection of vertebrate mammals used for experimentation and other scientific purposes).

Consent for publication
Not applicable.

Competing interests
The authors declare no conflict of interest.

Author details
1Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Av. Complutense 40, 28040 Madrid, Spain. 2Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Melchor Fernández Almagro 3, 28029 Madrid, Spain. 3Instituto de Investigación Sanitaria Fundación Jiménez Díaz (CIBERER), Melchor Fernández Almagro 3, 28029 Madrid, Spain. 4Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Av. Complutense 40, 28040 Madrid, Spain. 5Instituto de Investigación Sanitaria Fundación Jiménez Díaz (CIBERER), Melchor Fernández Almagro 3, 28029 Madrid, Spain. 6Instituto de Investigación Sanitaria Fundación Jiménez Díaz (CIBERER), Melchor Fernández Almagro 3, 28029 Madrid, Spain. 7Instituto de Investigación Sanitaria Fundación Jiménez Díaz (CIBERER), Melchor Fernández Almagro 3, 28029 Madrid, Spain. 8Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Av. Complutense 40, 28040 Madrid, Spain. 9Instituto de Investigación Sanitaria Fundación Jiménez Díaz (CIBERER), Melchor Fernández Almagro 3, 28029 Madrid, Spain.

Received: 13 November 2018 Revised: 18 March 2020 Accepted: 8 April 2020

Published online: 28 April 2020

References
1. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–87.
2. Zhang Y, Wang H. Integrin signalling and function in immune cells. Immunology. 2012;135(4):268–75.
3. Tan SM. The leucocyte beta2 (CD18) integrins: the structure, functional regulation and signalling properties. Biol Rep. 2012;32(2):241–69.
4. Torensma R, et al. Induction of LFA-1 on pluripotent CD34+ bone marrow cells does not affect lineage commitment. Blood. 1996;87(10):4120–8.
5. Torensma R, et al. Regulation of LFA-1 expression by CD34 positive cells and inducible growth factor production by stroma enable formation of bone marrow compartments; Subject: Hairdress. Hematology. 2000;5(4):295–302.
6. Gunji Y, et al. Expression and function of adhesion molecules on human hematopoietic stem cells: CD34+ LFA-1- cells are more primitive than CD34+ LFA-1+ cells. Blood. 1992;80(2):429–36.
7. Fathman JW, et al. Upregulation of CD11A on hematopoietic stem cells denotes the loss of long-term reconstitution potential. Stem Cell Reports. 2014;3(5):707–15.
8. Van Beusechem WW, et al. Gene transfer into nonhuman primate CD34+ CD11b- bone marrow progenitor cells capable of repopulating lymphoid and myeloid lineages. Hum Gene Ther. 1994;5(3):295–305.
9. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347(1–2):70–8.
10. Notta F, et al. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science. 2011;333(6039):218–21.
11. Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell. 2007;1(6): 635–45.
12. Boulais PE, Fenrette PS. Making sense of hematopoietic stem cells niches. Blood. 2015;125(17):2621–9.
13. Wong WM, et al. Expression of integrin alpha2 receptor in human cord blood CD34+CD38-CD90+ stem cells engrafting long-term in NOD/SCID-IL2Rgamma(c) null mice. Stem Cells. 2013;31(2):560–71.
14. Scott LM, Priestley GV, Papayannopoulou T. Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol Cell Biol. 2003;23(4):9349–60.
15. Gigant C, et al. CD34+ cells homing: quantitative expression of adhesion molecules and adhesion of CD34+ cells to endothelial cells exposed to shear stress. Biochimie. 2003;85(1–3):189–95.
16. Gigant C, et al. Quantitative expression of adhesion molecules on granulocyte colony-stimulating factor-mobilized peripheral blood, bone marrow, and cord blood CD34+ cells. J Hematother Stem Cell Res. 2001; 10(6):807–14.
17. Mohle R, et al. Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. Exp Hematol. 1995;23(14):1535–42.
18. Gomez JC, Doerschuk CM. The role of CD18 in the production and release of neutrophils from the bone marrow. Lab Invest. 2010;90(4):599–610.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.